ATLANTA— In patients with a variety of cancers oral therapy with edoxaban—a direct oral anticoagulant (DOAC)—was just as effective and safe in terms of the risks of recurrent venous thromboembolism (V
ATLANTA— In patients with a variety of cancers oral therapy with edoxaban—a direct oral anticoagulant (DOAC)—was just as effective and safe in terms of the risks of recurrent venous thromboembolism (VTE) and bleeding as injections with the low molecular weight heparin (LMWH) dalteparin in the multinational randomized Hokusai VTE-Cancer Study reported at the 2017 American Society of Hematology annual meeting.
“[The] findings show that the edoxaban treatment is non-inferior to the low molecular weight heparin therapy,” said lead author Gary E. Raskob PhD, Dean of the College of Public Health and Professor of Medicine and Epidemiology at the University of Oklahoma in Oklahoma City.
READ MORE from the American Society of Hematology Meeting in Oncology Times.
Tags
Related Episodes
Large Risk Reduction For Rivaroxaban In Blood Clot Prevention
Bengt Eriksson REFERENCE: Abstract 6, American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta BENGT ERIKSSON, Gothenburg University In a large phase III trial of patients having a h
Audio Journal of Cardiovascular Medicine: September 5th 2006
Shamir Mehta Keith Fox Petr Widimsky Gerrit Veen OASIS 5 & 6: Fondaparinux Anticoagulation: Benefit on Mortality, Events and Bleeding in Acute Coronary Syndromes and ST-Elevation Myocardial Infarc
Othman Al-Sawaf MD PhD; ASH 2025: Fixed-Duration Targeted Combinations As Effective as Extended Monotherapy for Patients with Untreated Chronic Lymphocytic Leukemia
Othman Al-Sawaf MD PhD, a hematologist from University Hospital of Cologne, presents early data from the CLL17 international phase three trial at ASH 2025. The findings indicate that fixed-duration treatment with venetoclax plus obinutuzumab or venetoclax plus ibrutinib is non-inferior to continuous ibrutinib for patients with previously untreated chronic lymphocytic leukemia, potentially becoming the preferred treatment.